Design of Potent Menin–KMT2A Interaction Inhibitors with Improved In Vitro ADME Properties and Reduced hERG Affinity
- 31 December 2024
- journal article
- research article
- Published by American Chemical Society (ACS) in ACS Medicinal Chemistry Letters
- Vol. 16 (2) , 224-233
Abstract
Inhibitors of the interaction of menin (MEN1) with lysine methyltransferase 2A (KMT2A) have emerged as novel therapeutic options in the treatment of genetically defined acute leukemias. Herein, we describe the structure-based design, synthesis, and biological evaluation of novel inhibitors of the menin-KMT2A interaction. Our structure-activity relationship campaign focused on achieving high antiproliferative cellular activity while mitigating risks associated with CYP3A4-dependent metabolism and hERG inhibition, which were characterized in some early clinical candidates. Our efforts resulted in the discovery of a triazine-based compound series that inhibited MV4-11 leukemia cell line proliferation with IC50 as low as 13 nM, and selected compounds demonstrated improved in vitro ADME properties, de-risked CYP3A4 dependency, and lower hERG inhibition.Keywords
This publication has 23 references indexed in Scilit:
- Small Molecule Menin Inhibitors: Novel Therapeutic Agents Targeting Acute Myeloid Leukemia with KMT2A Rearrangement or NPM1 MutationOncology and Therapy, 2024
- Recent Progress of Small Molecule Menin–MLL Interaction Inhibitors as Therapeutic Agents for Acute LeukemiaJournal of Medicinal Chemistry, 2021
- A Menin-MLL Inhibitor Induces Specific Chromatin Changes and Eradicates Disease in Models of MLL-Rearranged LeukemiaCancer Cell, 2019
- Drug-Induced Long QT Syndrome and Torsades de Pointes2019
- Experimentally Validated hERG Pharmacophore Models as Cardiotoxicity Prediction ToolsJournal of Chemical Information and Modeling, 2014
- High-Affinity Small-Molecule Inhibitors of the Menin-Mixed Lineage Leukemia (MLL) Interaction Closely Mimic a Natural Protein–Protein InteractionJournal of Medicinal Chemistry, 2014
- The Menin Tumor Suppressor Protein Is an Essential Oncogenic Cofactor for MLL-Associated LeukemogenesisCell, 2005
- Structure−Activity Relationships of 1-Alkyl-5-(3,4-dichlorophenyl)- 5-{2-[(3-substituted)-1-azetidinyl]ethyl}-2-piperidones. 1. Selective Antagonists of the Neurokinin-2 ReceptorJournal of Medicinal Chemistry, 2002
- Toward a Pharmacophore for Drugs Inducing the Long QT Syndrome: Insights from a CoMFA Study of HERG K+ Channel BlockersJournal of Medicinal Chemistry, 2002
- Long QT syndromes and torsade de pointesThe Lancet, 1999